News

Article

Strategic investment between Topcon and Pangaea

Author(s):

Key Takeaways

  • Topcon Healthcare's investment in Pangaea Data aims to address care gaps in eye health and systemic diseases using AI technology.
  • Pangaea's platform analyzes patient records to identify untreated patients, with proven efficacy in multiple therapeutic areas.
SHOW MORE

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

Image courtesy of Topcon Healthcare

Image courtesy of Topcon Healthcare

Topcon Healthcare recently announced a strategic investment of Pangaea Data, an AI health company that specializes in identifying untreated and undertreated patients at scale.1

The goal of the partnership between Topcon and Pangaea is to “accelerate the application of Pangaea’s clinically validated AI platform to address critical care gaps in eye health and systemic disease,” according to a press release.

Pangaea’s platform is designed to automatically analyze structured and unstructured patient records against clinical guidelines. Through the platform, patients who meet diagnostic or treatment criteria can be identified for treatment and management options.

The platform has already demonstrated its role across other therapeutic areas: pulmonology, cardiology, oncology, nephrology, and infection disease.

“We are thrilled to partner with Topcon Healthcare to scale our platform’s reach and improve timely diagnosis and treatment across eye care,” said Vibhor Gupta, PhD, founder and CEO of Pangaea Data. “Together, we can empower providers to close care gaps while generating actionable insights for population health, discovery science, and value-based care.”

Topcon’s Harmony digital health platform will be utilized to create a “seamless interface” for both optometry and ophthalmology practices to be able to identify patients who could benefit from and need follow-up or further evaluation.

Patients who will benefit from this include patients with glaucoma and patients with diabetic retinopathy (FR). More than 50% of glaucoma patients remain undiagnosed in the United States, and more than one-third of patients with DR do not receive the recommended annual eye screening.1

“Pangaea Data’s unique ability to find missed patients using AI, and to do so without burdening clinicians, has powerful implications for eye care and beyond,” said Ali Tafreshi, CEO and president of Topcon. “This partnership supports our Healthcare from the Eye initiative, which uses ocular data and AI to transform how systemic ocular diseases are detected and managed. We are proud to support Pangaea Data’s mission through this strategic investment.”

Reference:
1. jgrodriguez. Pangaea Data Secures Strategic Investment from Topcon Healthcare, Inc. to Close Global Care Gaps in Eye Health. Topcon Healthcare. Published May 27, 2025. Accessed May 27, 2025. https://topconhealthcare.com/article/pangaea-data-secures-strategic-investment-from-topcon-healthcare-inc-to-close-global-care-gaps-in-eye-health/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
© 2025 MJH Life Sciences

All rights reserved.